The use of percutaneous corory intervention to remove occlusions from corory arteries has increased substantially over recent years. Concurrent with the use of percutaneous corory intervention, the use of lipid-lowering medications, such as statins, has increased. The Lescol Intervention and Prevention Study showed significant reductions with statins in postpercutaneous corory intervention cardiac events. The cost- effectiveness of initiating statin use for all percutaneous corory intervention patients is favorable, with significant health benefits (including improved survival) for relatively low additiol costs (e.g., 㳲07 per quality-adjusted life year in the UK). Fluvastatin is the lowest cost statin currently available (less than the price of generic statins). Key economic issues include estimates of the current use of statins at the time of percutaneous corory intervention and the likelihood of switching from more expensive statins to fluvastatin.
Unless otherwise indicated, works by Griffith University Scholars are © Griffith University. For further details please refer to the University Intellectual Property Policy.